Clinical pharmacology consultation and outcomes associated with pregnancy exposure to FDA X Drugs
Results In pregnancies with available outcomes, the most frequently FDA-X prescribed drugs were oral contraceptives (53%), followed by paroxetin (21%), medroxiprogesterone (8%), retinoids (7%), warfarin (4%), methotrexate, statins, ribavirin, ulipristal-acetate, and radioactive iodine.
Gespeichert in:
| Veröffentlicht in: | Clinical therapeutics 2015-08, Vol.37 (8), p.e14-e15 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e15 |
|---|---|
| container_issue | 8 |
| container_start_page | e14 |
| container_title | Clinical therapeutics |
| container_volume | 37 |
| creator | Erdeljic Turk, V Francetic, I Makar Ausperger, K Likic, R Radacic-Aumiler, M |
| description | Results In pregnancies with available outcomes, the most frequently FDA-X prescribed drugs were oral contraceptives (53%), followed by paroxetin (21%), medroxiprogesterone (8%), retinoids (7%), warfarin (4%), methotrexate, statins, ribavirin, ulipristal-acetate, and radioactive iodine. |
| doi_str_mv | 10.1016/j.clinthera.2015.05.051 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1693873865</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0149291815003586</els_id><sourcerecordid>3735386321</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2381-7ec4f3410bf415e28d9a63b3cfdac555bb3bfcfc7f8804ceaba9d6cf245c64943</originalsourceid><addsrcrecordid>eNqNUcFq3DAUFKWFbtN8QwU9eytZki1fCsumaQKBHpJAbkJ-ftrV1mu5kpx2_742G1roqTDwLjPz3psh5ANna8549emwht4PeY_RrkvG1Zot4K_Iiuu6KTiXT6_JinHZFGXD9VvyLqUDY0w0qlwRu53FHmxPx72NRwuhD7sThTCkqc82-zBQO3Q0TBnCERO1KQXwNmNHf_q8p2PE3WAHOFH8NYY0RaQ50OurDX2iV3HapffkjbN9wsuXeUEer788bG-Ku29fb7ebuwJKoXlRI0gnJGetk1xhqbvGVqIV4DoLSqm2Fa0DB7XTmklA29qmq8CVUkElGykuyMez7xjDjwlTNocwxWFeaXjVCF0LXamZVZ9ZEENKEZ0Zoz_aeDKcmSVPczB_8jRLnoYt4LNyc1bi_MSzx2gSeBwAOx8RsumC_w-Pz_94wEv83_GE6e_BJpWGmfultaU0rua-lK7Eb0dsmf8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1693873865</pqid></control><display><type>article</type><title>Clinical pharmacology consultation and outcomes associated with pregnancy exposure to FDA X Drugs</title><source>Elsevier ScienceDirect Journals</source><creator>Erdeljic Turk, V ; Francetic, I ; Makar Ausperger, K ; Likic, R ; Radacic-Aumiler, M</creator><creatorcontrib>Erdeljic Turk, V ; Francetic, I ; Makar Ausperger, K ; Likic, R ; Radacic-Aumiler, M</creatorcontrib><description>Results In pregnancies with available outcomes, the most frequently FDA-X prescribed drugs were oral contraceptives (53%), followed by paroxetin (21%), medroxiprogesterone (8%), retinoids (7%), warfarin (4%), methotrexate, statins, ribavirin, ulipristal-acetate, and radioactive iodine.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2015.05.051</identifier><language>eng</language><publisher>Bridgewater: Elsevier Inc</publisher><subject>Abortion ; Birth weight ; Drugs ; Health risk assessment ; Internal Medicine ; Medical Education ; Pregnancy ; Women</subject><ispartof>Clinical therapeutics, 2015-08, Vol.37 (8), p.e14-e15</ispartof><rights>2015</rights><rights>Copyright Elsevier Limited Aug 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0149291815003586$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids></links><search><creatorcontrib>Erdeljic Turk, V</creatorcontrib><creatorcontrib>Francetic, I</creatorcontrib><creatorcontrib>Makar Ausperger, K</creatorcontrib><creatorcontrib>Likic, R</creatorcontrib><creatorcontrib>Radacic-Aumiler, M</creatorcontrib><title>Clinical pharmacology consultation and outcomes associated with pregnancy exposure to FDA X Drugs</title><title>Clinical therapeutics</title><description>Results In pregnancies with available outcomes, the most frequently FDA-X prescribed drugs were oral contraceptives (53%), followed by paroxetin (21%), medroxiprogesterone (8%), retinoids (7%), warfarin (4%), methotrexate, statins, ribavirin, ulipristal-acetate, and radioactive iodine.</description><subject>Abortion</subject><subject>Birth weight</subject><subject>Drugs</subject><subject>Health risk assessment</subject><subject>Internal Medicine</subject><subject>Medical Education</subject><subject>Pregnancy</subject><subject>Women</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNUcFq3DAUFKWFbtN8QwU9eytZki1fCsumaQKBHpJAbkJ-ftrV1mu5kpx2_742G1roqTDwLjPz3psh5ANna8549emwht4PeY_RrkvG1Zot4K_Iiuu6KTiXT6_JinHZFGXD9VvyLqUDY0w0qlwRu53FHmxPx72NRwuhD7sThTCkqc82-zBQO3Q0TBnCERO1KQXwNmNHf_q8p2PE3WAHOFH8NYY0RaQ50OurDX2iV3HapffkjbN9wsuXeUEer788bG-Ku29fb7ebuwJKoXlRI0gnJGetk1xhqbvGVqIV4DoLSqm2Fa0DB7XTmklA29qmq8CVUkElGykuyMez7xjDjwlTNocwxWFeaXjVCF0LXamZVZ9ZEENKEZ0Zoz_aeDKcmSVPczB_8jRLnoYt4LNyc1bi_MSzx2gSeBwAOx8RsumC_w-Pz_94wEv83_GE6e_BJpWGmfultaU0rua-lK7Eb0dsmf8</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Erdeljic Turk, V</creator><creator>Francetic, I</creator><creator>Makar Ausperger, K</creator><creator>Likic, R</creator><creator>Radacic-Aumiler, M</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20150801</creationdate><title>Clinical pharmacology consultation and outcomes associated with pregnancy exposure to FDA X Drugs</title><author>Erdeljic Turk, V ; Francetic, I ; Makar Ausperger, K ; Likic, R ; Radacic-Aumiler, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2381-7ec4f3410bf415e28d9a63b3cfdac555bb3bfcfc7f8804ceaba9d6cf245c64943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Abortion</topic><topic>Birth weight</topic><topic>Drugs</topic><topic>Health risk assessment</topic><topic>Internal Medicine</topic><topic>Medical Education</topic><topic>Pregnancy</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erdeljic Turk, V</creatorcontrib><creatorcontrib>Francetic, I</creatorcontrib><creatorcontrib>Makar Ausperger, K</creatorcontrib><creatorcontrib>Likic, R</creatorcontrib><creatorcontrib>Radacic-Aumiler, M</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erdeljic Turk, V</au><au>Francetic, I</au><au>Makar Ausperger, K</au><au>Likic, R</au><au>Radacic-Aumiler, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical pharmacology consultation and outcomes associated with pregnancy exposure to FDA X Drugs</atitle><jtitle>Clinical therapeutics</jtitle><date>2015-08-01</date><risdate>2015</risdate><volume>37</volume><issue>8</issue><spage>e14</spage><epage>e15</epage><pages>e14-e15</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>Results In pregnancies with available outcomes, the most frequently FDA-X prescribed drugs were oral contraceptives (53%), followed by paroxetin (21%), medroxiprogesterone (8%), retinoids (7%), warfarin (4%), methotrexate, statins, ribavirin, ulipristal-acetate, and radioactive iodine.</abstract><cop>Bridgewater</cop><pub>Elsevier Inc</pub><doi>10.1016/j.clinthera.2015.05.051</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-2918 |
| ispartof | Clinical therapeutics, 2015-08, Vol.37 (8), p.e14-e15 |
| issn | 0149-2918 1879-114X |
| language | eng |
| recordid | cdi_proquest_journals_1693873865 |
| source | Elsevier ScienceDirect Journals |
| subjects | Abortion Birth weight Drugs Health risk assessment Internal Medicine Medical Education Pregnancy Women |
| title | Clinical pharmacology consultation and outcomes associated with pregnancy exposure to FDA X Drugs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T08%3A33%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20pharmacology%20consultation%20and%20outcomes%20associated%20with%20pregnancy%20exposure%20to%20FDA%20X%20Drugs&rft.jtitle=Clinical%20therapeutics&rft.au=Erdeljic%20Turk,%20V&rft.date=2015-08-01&rft.volume=37&rft.issue=8&rft.spage=e14&rft.epage=e15&rft.pages=e14-e15&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2015.05.051&rft_dat=%3Cproquest_cross%3E3735386321%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1693873865&rft_id=info:pmid/&rft_els_id=S0149291815003586&rfr_iscdi=true |